← Alle mensen

HZ

Huilai Zhang

7 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Blood · 15 januari 2026

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Re...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 december 2025

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B...

Lancet (London, England) · 16 november 2024

Golidocitinib (selectieve JAK1-remmer) bij refractair/recidief perifeer T-cellymfoom

The Lancet. Oncology · 2024-01

Zanubrutinib plus obinutuzumab versus obinutuzumab bij recidief/refractair FL: ROSEWOOD fase II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 november 2023

Pola-R-CHP bij onbehandeld DLBCL: Aziatische POLARIX subanalyse

Blood · 20 april 2023

Lenalidomide plus rituximab versus placebo plus rituximab bij recidief indolent NHL: AUGMENT fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 mei 2019